An analysis of reports of depression and suicide in patients treated with isotretinoin - PubMed (original) (raw)
An analysis of reports of depression and suicide in patients treated with isotretinoin
D K Wysowski et al. J Am Acad Dermatol. 2001 Oct.
Abstract
Background: The Food and Drug Administration (FDA) has received reports of depression and suicide in patients treated with isotretinoin.
Objective: Our purpose was to provide the number and describe the cases of depression and suicide reported to the FDA in US patients treated with isotretinoin and to consider the nature of a possible association between isotretinoin and depression.
Methods: An analysis was made of reports of depression, suicidal ideation, suicide attempt, and suicide in US isotretinoin users voluntarily submitted to the manufacturer and the FDA from 1982 to May 2000 and entered in the FDA's Adverse Event Reporting System database.
Results: From marketing of isotretinoin in 1982 to May 2000, the FDA received reports of 37 US patients treated with isotretinoin who committed suicide; 110 who were hospitalized for depression, suicidal ideation, or suicide attempt; and 284 with nonhospitalized depression, for a total of 431 patients. Factors suggesting a possible association between isotretinoin and depression include a temporal association between use of the drug and depression, positive dechallenges (often with psychiatric treatment), positive rechallenges, and possible biologic plausibility. Compared with all drugs in the FDA's Adverse Event Reporting System database to June 2000, isotretinoin ranked within the top 10 for number of reports of depression and suicide attempt.
Conclusion: The FDA has received reports of depression, suicidal ideation, suicide attempt, and suicide in patients treated with isotretinoin. Additional studies are needed to determine whether isotretinoin causes depression and to identify susceptible persons. In the meantime, physicians are advised to inform patients prescribed isotretinoin (and parents, if appropriate) of the possibility of development or worsening of depression. They should advise patients (and parents) to immediately report mood swings and symptoms suggestive of depression such as sadness, crying, loss of appetite, unusual fatigue, withdrawal, and inability to concentrate so that patients can be promptly evaluated for appropriate treatment, including consideration of drug discontinuation and referral for psychiatric care.
Similar articles
- Psychiatric reactions to isotretinoin in patients with bipolar disorder.
Schaffer LC, Schaffer CB, Hunter S, Miller A. Schaffer LC, et al. J Affect Disord. 2010 May;122(3):306-8. doi: 10.1016/j.jad.2009.09.005. Epub 2009 Sep 27. J Affect Disord. 2010. PMID: 19783054 - Depression and suicide in patients treated with isotretinoin.
Wysowski DK, Pitts M, Beitz J. Wysowski DK, et al. N Engl J Med. 2001 Feb 8;344(6):460. doi: 10.1056/NEJM200102083440616. N Engl J Med. 2001. PMID: 11221610 No abstract available. - [Psychiatric symptoms during isotretinoin therapy].
van Broekhoven F, Verkes RJ, Janzing JG. van Broekhoven F, et al. Ned Tijdschr Geneeskd. 2003 Nov 22;147(47):2341-3. Ned Tijdschr Geneeskd. 2003. PMID: 14669543 Dutch. - Depression and acitretin: a true association or a class labeling?
Hayes J, Koo J. Hayes J, et al. J Drugs Dermatol. 2011 Apr;10(4):409-12. J Drugs Dermatol. 2011. PMID: 21455552 Review. - Isotretinoin use and subsequent depression and suicide: presenting the evidence.
Hull PR, D'Arcy C. Hull PR, et al. Am J Clin Dermatol. 2003;4(7):493-505. doi: 10.2165/00128071-200304070-00005. Am J Clin Dermatol. 2003. PMID: 12814338 Review.
Cited by
- Treatment of Acute Psychosis Caused by Isotretinoin: Systematic Review.
Stanojkovic T, Zivkovic Zaric R, Lesnjak I, Gajic M, Markovic S, Canovic A, Jankovic Jovanovic K. Stanojkovic T, et al. Psychiatry Clin Psychopharmacol. 2024 Jun 1;34(2):103-108. doi: 10.5152/pcp.2024.23778. eCollection 2024 Jun. Psychiatry Clin Psychopharmacol. 2024. PMID: 39165893 Free PMC article. - Practice and attitude of general practitioners towards initiating isotretinoin for acne vulgaris in Fars province, Iran: cross-sectional study.
Hosseinpour P, Gholamabbas G, Pezeshkian F, Erfani A, Shahriarirad R, Parhizkar AR. Hosseinpour P, et al. BMC Prim Care. 2024 Jan 13;25(1):27. doi: 10.1186/s12875-023-02260-w. BMC Prim Care. 2024. PMID: 38216903 Free PMC article. - Design and Evaluation of Tretinoin Fatty Acid Vesicles for the Topical Treatment of Psoriasis.
Zhao Y, Wang C, Zou B, Fu L, Ren S, Zhang X. Zhao Y, et al. Molecules. 2023 Nov 30;28(23):7868. doi: 10.3390/molecules28237868. Molecules. 2023. PMID: 38067597 Free PMC article. - Isotretinoin and neuropsychiatric side effects: Continued vigilance is needed.
Bremner JD. Bremner JD. J Affect Disord Rep. 2021 Dec;6:100230. doi: 10.1016/j.jadr.2021.100230. Epub 2021 Sep 10. J Affect Disord Rep. 2021. PMID: 37168254 Free PMC article. - Spotting fake news: a qualitative review of misinformation and conspiracy theories in acne vulgaris.
O'Connor C, O'Grady C, Murphy M. O'Connor C, et al. Clin Exp Dermatol. 2022 Sep;47(9):1707-1711. doi: 10.1111/ced.15222. Epub 2022 May 28. Clin Exp Dermatol. 2022. PMID: 35434841 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical